| Dermatitis, Atopic
Cibinqo vs Dupixent
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Cibinqo vs Dupixent with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDupixent has a higher rate of injection site reactions vs Cibinqo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Dupixent but not Cibinqo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cibinqo
Dupixent
At A Glance
Oral
Once daily
JAK inhibitor
SC injection
Every 2 weeks
IL-4Ra antagonist
Indications
- Dermatitis, Atopic
- Dermatitis, Atopic
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- Eosinophilic esophagitis
- Prurigo nodularis
- Chronic Obstructive Airway Disease
- Chronic Spontaneous Urticaria
- Bullous pemphigoid
- Allergic Fungal Rhinosinusitis
Dosing
Dermatitis, Atopic 100 mg orally once daily; may increase to 200 mg once daily for inadequate response. In moderate renal impairment or CYP2C19 poor metabolizers: 50 mg once daily, may increase to 100 mg once daily for inadequate response.
Dermatitis, Atopic Adults: 600 mg initial dose, then 300 mg SC Q2W; pediatric patients 6 months to 5 years: weight-based Q4W without loading dose; pediatric patients >=6 years: weight-based loading dose then Q2W or Q4W.
Asthma Adults and pediatric >=12 years: 400 mg or 600 mg loading dose, then 200 mg or 300 mg SC Q2W; pediatric 6-11 years: weight-based Q2W or Q4W without loading dose.
Chronic rhinosinusitis with multiple nasal polyps 300 mg SC Q2W for adults and pediatric patients >=12 years.
Eosinophilic esophagitis SC weight-based dosing for patients >=1 year weighing >=15 kg: 200 mg Q2W (15 to <30 kg), 300 mg Q2W (30 to <40 kg), or 300 mg weekly (>=40 kg).
Prurigo nodularis Adults: 600 mg initial dose, then 300 mg SC Q2W.
Chronic Obstructive Airway Disease Adults: 300 mg SC Q2W.
Chronic Spontaneous Urticaria Adults: 600 mg initial dose, then 300 mg SC Q2W; pediatric 12-17 years: weight-based 400 mg or 600 mg loading, then 200 mg or 300 mg Q2W.
Bullous pemphigoid Adults: 600 mg initial dose, then 300 mg SC Q2W in combination with a tapering course of oral corticosteroids.
Allergic Fungal Rhinosinusitis Adults: 300 mg SC Q2W; pediatric 6-17 years: weight-based Q2W or Q4W (15 to <30 kg: 300 mg Q4W; 30 to <60 kg: 200 mg Q2W; >=60 kg: 300 mg Q2W).
Contraindications
- Patients taking antiplatelet therapies (except low-dose aspirin <=81 mg daily) during the first 3 months of treatment
- Known hypersensitivity to dupilumab or any excipients of DUPIXENT
Adverse Reactions
Most common (>=1%) Nasopharyngitis (8.7-12.4%), nausea (6.0-14.5%), headache (6.0-7.8%), herpes simplex (3.3-4.2%), increased blood creatine phosphokinase (2.3-2.9%), dizziness (1.8-2.9%), urinary tract infection (1.7-2.2%), fatigue (1.3-1.6%), acne (1.6-4.7%), vomiting (1.5-3.2%), impetigo (0.5-1.5%), oropharyngeal pain (1.0-1.4%), hypertension (0.8-1.2%), influenza (1.1-1.2%), gastroenteritis (1.1-1.3%), dermatitis contact (0.5-1.1%), abdominal pain upper (0.6-1.9%), abdominal discomfort (0.5-1.2%), herpes zoster (0.3-1.2%), thrombocytopenia (0-1.5%)
Serious Serious infections including herpes simplex, herpes zoster, and pneumonia (2.3 per 100 patient-years); thrombosis including pulmonary embolism and deep vein thrombosis; major adverse cardiovascular events; malignancy; retinal detachment
Most common (>=1%) Injection site reactions, conjunctivitis, oral herpes, blepharitis, keratitis, eye pruritus, other herpes simplex virus infection, dry eye
Serious Hypersensitivity reactions, conjunctivitis and keratitis, psoriasis, arthralgia and psoriatic arthritis, parasitic (helminth) infections
Postmarketing Angioedema, psoriatic arthritis, facial skin reactions (erythema, rash, scaling, edema, papules, pruritus, burning, pain), new-onset psoriasis, vasculitis
Pharmacology
Abrocitinib is a Janus kinase (JAK) inhibitor that reversibly inhibits JAK1 by blocking the ATP binding site. It is selective for JAK1 over JAK2 (28-fold), JAK3 (>340-fold), and TYK2 (43-fold).
Dupilumab is a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 signaling by binding to the IL-4Ra subunit shared by the IL-4 and IL-13 receptor complexes, blocking cytokine-induced inflammatory responses including release of proinflammatory cytokines, chemokines, nitric oxide, and IgE.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cibinqo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Dupixent
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (2/12)
UnitedHealthcare
Cibinqo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Dupixent
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (6/8)
Humana
Cibinqo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Dupixent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Atopic Dermatitis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell Foundation: Asthma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CibinqoView full Cibinqo profile
DupixentView full Dupixent profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.